OBJECTIVE: The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of oropharyngeal mucositis (OM) after myeloablative allogeneic stem cell transplant (allo-SCT) with total body irradiation (TBI) conditioning. This approach has the advantage of avoiding methotrexate for graft versus host disease (GVHD) prophylaxis. PATIENTS AND METHODS: We analyzed the incidence and severity of OM in a cohort of 105 consecutive patients who underwent CD34+ selected (peripheral blood stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings) allo-SCT with total body irradiation (TBI) conditioning. OM was graded by the World Health organization (WHO) and the Bearman regimen-related toxicity (RRT) scales. RESULTS: The incidence of WHO grade 3-4 OM was 34.3 %. There were no cases of grade 3-4 OM by the RRT scale. Significant correlation was found between the severity of OM and the use of intravenous (IV) narcotic medications (r (2) = 0.15, p = 0.004), total parenteral nutrition (TPN; r (2) = 0.68, p < 0.001), and hospital length of stay (LOS) (r (2) = 0.12, p = 0.01). DISCUSSION: TBI-induced OM can inflict significant morbidity in the early transplant period, and the incidence of WHO grade 3-4 OM can exceed 50 % when methotrexate is used for GVHD prophylaxis. In the CD34+ selected setting, methotrexate is avoided and the incidence of WHO grade 3-4 OM, use of TPN, and need for narcotic analgesia appear to be lower than historic evidence from standard T-replete allogeneic transplantation. CONCLUSION: We conclude that toxicity from OM is tolerable in CD34+ selected allo-SCT and should be prospectively measured in randomized trials comparing CD34+ selection versus T-replete transplantation.
OBJECTIVE: The purpose of the present study was to evaluate the impact of ex vivo T cell depleted (TCD) by CD34+ selection on the incidence and severity of oropharyngeal mucositis (OM) after myeloablative allogeneic stem cell transplant (allo-SCT) with total body irradiation (TBI) conditioning. This approach has the advantage of avoiding methotrexate for graft versus host disease (GVHD) prophylaxis. PATIENTS AND METHODS: We analyzed the incidence and severity of OM in a cohort of 105 consecutive patients who underwent CD34+ selected (peripheral blood stem cells (PBSCs) from human leukocyte antigen (HLA)-identical siblings) allo-SCT with total body irradiation (TBI) conditioning. OM was graded by the World Health organization (WHO) and the Bearman regimen-related toxicity (RRT) scales. RESULTS: The incidence of WHO grade 3-4 OM was 34.3 %. There were no cases of grade 3-4 OM by the RRT scale. Significant correlation was found between the severity of OM and the use of intravenous (IV) narcotic medications (r (2) = 0.15, p = 0.004), total parenteral nutrition (TPN; r (2) = 0.68, p < 0.001), and hospital length of stay (LOS) (r (2) = 0.12, p = 0.01). DISCUSSION: TBI-induced OM can inflict significant morbidity in the early transplant period, and the incidence of WHO grade 3-4 OM can exceed 50 % when methotrexate is used for GVHD prophylaxis. In the CD34+ selected setting, methotrexate is avoided and the incidence of WHO grade 3-4 OM, use of TPN, and need for narcotic analgesia appear to be lower than historic evidence from standard T-replete allogeneic transplantation. CONCLUSION: We conclude that toxicity from OM is tolerable in CD34+ selected allo-SCT and should be prospectively measured in randomized trials comparing CD34+ selection versus T-replete transplantation.
Entities:
Keywords:
Allogeneic; CD34 selection; Methotrexate; Oral mucositis; Oropharyngeal mucositis; Quality of life; Stem cell transplant; T cell depleted transplantation; Total body irradiation
Authors: C M Ulrich; Y Yasui; R Storb; M M Schubert; J L Wagner; J Bigler; K S Ariail; C L Keener; S Li; H Liu; F M Farin; J D Potter Journal: Blood Date: 2001-07-01 Impact factor: 22.113
Authors: Ajay K Nooka; Heather R Johnson; Jonathan L Kaufman; Christopher R Flowers; Amelia Langston; Conor Steuer; Michael Graiser; Zahir Ali; Nishi N Shah; Sravanti Rangaraju; Dana Nickleach; Jingjing Gao; Sagar Lonial; Edmund K Waller Journal: Biol Blood Marrow Transplant Date: 2014-03-06 Impact factor: 5.742
Authors: Nicholas M Murphy; Mary Diviney; Jeff Szer; Peter Bardy; Andrew Grigg; Rosemary Hoyt; Belinda King-Kallimanis; Rhonda Holdsworth; James McCluskey; Brian D Tait Journal: Biol Blood Marrow Transplant Date: 2011-09-14 Impact factor: 5.742
Authors: Steven M Devine; Shelly Carter; Robert J Soiffer; Marcelo C Pasquini; Parameswaran N Hari; Anthony Stein; Hillard M Lazarus; Charles Linker; Edward A Stadtmauer; Edwin P Alyea; Carolyn A Keever-Taylor; Richard J O'Reilly Journal: Biol Blood Marrow Transplant Date: 2011-02-12 Impact factor: 5.742
Authors: E Schmidt; N H Thoennissen; A Rudat; R Bieker; C Schliemann; R M Mesters; M Zühlsdorf; C Müller-Tidow; W E Berdel Journal: Ann Oncol Date: 2008-05-02 Impact factor: 32.976
Authors: Linda S Elting; Ya-Chen Tina Shih; Patrick J Stiff; William Bensinger; Scott B Cantor; Catherine Cooksley; Ricardo Spielberger; Christos Emmanoulides Journal: Biol Blood Marrow Transplant Date: 2007-04-23 Impact factor: 5.742
Authors: Lisa A Bellm; Gail Cunningham; Laurie Durnell; June Eilers; Joel B Epstein; Tom Fleming; Henry J Fuchs; Martha Nash Haskins; Mary M Horowitz; Paul J Martin; Deborah B McGuire; Kevin Mullane; Gerry Oster Journal: Cancer Invest Date: 2002 Impact factor: 2.176
Authors: V Rocha; R Porcher; J F Fernandes; A Filion; H Bittencourt; W Silva; G Vilela; D L Zanette; C Ferry; J Larghero; A Devergie; P Ribaud; Y Skvortsova; R Tamouza; E Gluckman; G Socie; M A Zago Journal: Leukemia Date: 2008-11-13 Impact factor: 11.528